Preferred Label : Cyclin A/B RxL Inhibitor CID-078;
NCIt definition : An orally bioavailable macrocycle inhibitor of cyclin A and B RxL, with potential
antineoplastic activity. Upon oral administration, cyclin A/B RxL inhibitor CID-078
selectively targets and binds to the hydrophobic patch (HP) of cyclins A and B and
prevents cyclin A and B substrates containing RxL motifs from binding to cyclins A
and B, thereby preventing their interaction, including the interaction of the cyclin
A substrate E2F1 with cyclin A-cyclin-dependent kinase 2 (CDK2) and the cyclin B substrate
Myt1 with cyclin B-CDK1. This may lead to DNA cell damage and cell cycle arrest during
the G1/S transition, induce apoptosis, and inhibit proliferation of susceptible tumor
cells. Cyclins A and B play a key role in the regulation and progression of the cell
cycle and their function is dysregulated in certain tumor cell types.;
Molecule name : CID-078; CID 078;
Origin ID : C210641;
concept_is_in_subset
